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Background: The HIV epidemic in Russia is concentrated among injection drug users (IDUs). This is especially true
for St. Petersburg where high HIV incidence persists among the city’s estimated 80,000 IDUs. Although sterile
syringes are legally available, access for IDUs may be hampered. To explore the feasibility of using pharmacies to
expand syringe access and provide other prevention services to IDUs, we investigated the current access to sterile
syringes at the pharmacies and the correlation between pharmacy density and HIV prevalence in St. Petersburg.
Methods: 965 pharmacies citywide were mapped, classified by ownership type, and the association between
pharmacy density and HIV prevalence at the district level was tested. We selected two districts among the 18
districts – one central and one peripheral – that represented two major types of city districts and contacted all
operating pharmacies by phone to inquire if they stocked syringes and obtained details about their stock.
Qualitative interviews with 26 IDUs provided data regarding syringe access in pharmacies and were used to
formulate hypotheses for the pharmacy syringe purchase test wherein research staff attempted to purchase
syringes in all pharmacies in the two districts.
Results: No correlation was found between the density of pharmacies and HIV prevalence at the district level. Of
108 operating pharmacies, 38 (35%) did not sell syringes of the types used by IDUs; of these, half stocked but
refused to sell syringes to research staff, and the other half did not stock syringes at all. Overall 70 (65%) of the
pharmacies did sell syringes; of these, 49 pharmacies sold single syringes without any restrictions and 21 offered
packages of ten.
Conclusions: Trainings for pharmacists need to be conducted to reduce negative attitudes towards IDUs and
increase pharmacists’ willingness to sell syringes. At a structural level, access to safe injection supplies for IDUs
could be increased by including syringes in the federal list of mandatory medical products sold by pharmacies.
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The HIV epidemic in Russia, which began in the late
1990’s, has been largely concentrated among people who
inject drugs [1-3]. Through 2009, 567,558 cases of HIV
have been identified, with more than 10% added in 2009
alone [4]. Estimates suggest that more than 1.2 million* Correspondence: ekaterina_fedorova@yahoo.com
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reproduction in any medium, provided the orRussians are infected with HIV, with 82% reporting
injection drug use (IDU) [1,5].
St. Petersburg, the second largest city in Russia with a
population of 5 million registered inhabitants, experi-
enced an expanding heroin market in the late 1990’s and
a subsequent epidemic of HIV. Presently, among the
city’s estimated 83,000 IDUs [6], about 82% of IDUs
inject heroin as their primary drug, and about 18% inject
ephedrine-based stimulants [7]. As of 2009, more than
38,000 individuals had been diagnosed with HIV with
76.4% of cases attributed to injection drug use [8]. HIVral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high, increasing from <5% prior to 2000 to 30% in 2003
and to 44% in 2007 [9-11]. In longitudinal cohorts of
IDUs, HIV incidence was 4.5 per 100 person-years in
2003 and 7.2 per 100 person-years in 2009 [12,13].
HIV transmission among IDUs results primarily from
unsafe injection practices such as the sharing of used
syringes due to the lack of access to sufficient supply of
sterile syringes [14,15]. This is often considered a struc-
tural issue related to law and public policies. This has
been especially true in the U.S., where laws have
restricted access [16-18]. Outside of the U.S. where
access is not legally restricted, the extent to which local
pharmacies are willing to sell syringes to IDUs is an
important factor shaping epidemic control efforts. In
Edinburgh, Scotland, for example, an outbreak of HIV
among IDUs in the mid-1980’s has been attributed to a
decision reached by pharmacists and the police to halt
sales of syringes to customers who appeared to be IDUs
by subjective judgment [19]. Studies on expanding ac-
cess have been conducted in several locations, most
notably in the U.S. [20,21], in the wake of changing laws
that allowed purchase and possession of syringes without
prescription [22,23]. Large-scale expansion of targeted
sales of syringes to IDUs from pharmacies has been
shown to contribute to maintaining low prevalence of
HIV-1 among Australian and British IDUs and lowering
HIV incidence in New York City [24-26]. However, most
studies on syringe access, even those undertaken most
recently [27,28], have focused on locations in which
syringe sales had been legally restricted in some way.
The situation is very different in St. Petersburg, Russia.
According to Russian federal laws and regulations,
syringes can be sold in all pharmacies without legal limi-
tations. However, there are often gaps between the formal
laws and their street-level implementation [16,29,30].
Syringes and condoms are not included in the required
pharmacy formulary as stated in the governing decree,
“On minimal assortment of medicinal agents” and
approved by the Ministry of Healthcare and Social Devel-
opment [31]. Accordingly, availability of syringes in a
pharmacy is not regulated by any legal act but varies with
commercial polices of the specific pharmacies. Thus, de-
clining to sell syringes is not a violation. It is important to
note that since there are very few syringe exchange pro-
grams in St. Petersburg, pharmacies are the primary
source of syringes for IDUs [32].
The “International Feasibility Study of Pharmacy-Based
HIV Prevention” is a multi-site, cross-sectional, multi-
phase, multi-methods research project – three sites are
located in the U. S. and the other three – in China, Russia
and Vietnam. The aim of the collaborative project is to
evaluate the feasibility of implementing pharmacy-based
interventions to reduce HIV transmission among IDUs. Inthis manuscript, we examine syringe access at the phar-
macies of St. Petersburg including stocking and sales prac-
tices as one of the multi-site study objectives. Specifically,
we explored the role of syringe access ecologically and,
focusing on two of the city’s 18 districts, examined how
pharmacies’ business models and their stocking and sales
practices may influence access. First, we tested the
hypothesis that since syringe access was not legally
restricted, those districts with a higher pharmacy density
would have lower rates of HIV infection. Second, we
sought to understand differences between policy and prac-
tice by attempting to purchase syringes at each pharmacy
in the two districts.
Methods
To evaluate syringe access in St. Petersburg, pharmacy
mapping, a telephone survey of pharmacists, qualitative
interviews about the actual experiences of active IDUs
with pharmacists, and a syringe purchase test were
conducted from November 2009 through June 2010.
Citywide pharmacy mapping
First, we identified and mapped pharmacies throughout
the city to evaluate whether pharmacy density could ex-
plain the epidemic pattern at the district level. We used
the Russian search term “аптека” [pharmacy] on Google
maps to identify pharmacy location and Quantum GIS
to generate a map of pharmacy density in relationship
with data on HIV prevalence in residential areas of the
city [33]. We obtained the official data on HIV preva-
lence by district from the City AIDS Center and data on
population density by district from the official electronic
source of the Federal Statistics Service [8,34]. Pearson
correlation coefficient was used to test the hypothesis
that the population-adjusted pharmacy density and HIV
prevalence were statistically correlated.
Selection of two study districts
Given the large number of pharmacies citywide, we
decided to select two city districts that differed based on
(1) proximity to the city center and (2) the distribution
of commercial to residential space. The Petrogradskiy
district is located in the city center, and encompasses 24
square kilometers containing commercial, recreational,
and residential facilities. As of 2009, its population was
124,800 inhabitants (population density: 5,200 persons
per square kilometer); the cumulative number of regis-
tered drug users was 138.16 per 100,000 inhabitants with
HIV prevalence in the district at 586.6 per 100,000. The
Viborgskiy district is located on the northern periphery
of the city, and encompasses 115.4 square kilometers
that is primarily residential. As of 2009, its population
was 410,000 inhabitants (population density: 3,565 per-
sons per square kilometer); the cumulative number of
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with HIV prevalence in the district at 597.86 per
100,000. Overall across the city districts, HIV prevalence
varied from 339.2 to 1143.6 per 100,000, and range for
the cumulative number of registered drug users was
24.53-220.42 per 100.000 inhabitants [8,34].
Pharmacy telephone survey
We conducted a brief telephone survey at each of the
pharmacies in the two selected city districts –
Petrogradskiy and Viborgskiy. A staff member called
each pharmacy and asked if the pharmacy stocked 1 or
2 ml syringes for sale. Although syringes are sold with
volumes from 1 to 20 ml capacity, the majority of IDUs
use 1 or 2 ml syringes. Data were recorded in an Excel
spreadsheet.
Qualitative interviews with IDUs
In preparation for a pharmacy syringe purchase test, we
used data from 26 semi-structured interviews with a
convenience sample of active IDUs. Participants were
recruited from an existing cohort followed at the Bio-
medical Center. All participants reported injecting illicit
drugs within a month prior to the interview. An inter-
view guide was developed for this study and focused on
IDUs’ past experiences with pharmacies and pharmacy
staff and attitudes towards a range of possible
pharmacy-based HIV prevention interventions. For this
manuscript we restricted the qualitative analysis to the
evaluation of IDUs’ past experiences of syringe purchase
in pharmacies. Interviews were audio-recorded, transcribed,
and coded using open and axial codes in a thematic
analysis. The interview guide and informed consent
forms were approved by the Yale University and the Bio-
medical Center Institutional Review Boards. Informed
consent was obtained from all participants, including
consent to be audio-recorded.
Pharmacy syringe purchase test
The pharmacy syringe purchase test was conducted in
all 108 pharmacies located in the two selected city dis-
tricts. We developed a standard script using methods
from Compton et al. [21]. The script was adapted to the
Russian setting, taking into account specific injection be-
haviors of local IDUs.
Three Russian male research assistants, experienced in
field work with IDUs, were involved in the syringe pur-
chase test. They were trained to follow the script using
the following protocol. Two members of the research
staff entered the pharmacy and asked for a single 1 ml
syringe and Naphazoline, a saline solution sold in glass
bottles which provides IDUs with both liquid to dissolve
drugs for injections and a receptacle (“cooker”) used to
prepare the injection. Qualitative data indicated thatthese two items are the most frequently requested
supplies that IDUs seek to buy. The research staff were
instructed to avoid any suggestion of deception in
research. There were no direct or indirect attempts,
either through dress or behavioral cues or through verbal
statements to suggest that the research staff were IDUs.
The standardized purchasing protocol had a number
of steps. If told that a single 1 ml syringe was not avail-
able, the researcher was instructed to ask for a single
2 ml syringe. If told that the pharmacy only sold syringes
in packs of ten, the research staff asked for and pur-
chased a pack of ten. If informed that the pharmacy sells
syringes only in quantities greater than ten, the research
staff inquired about the minimum quantity of purchase
and then declined to purchase. If informed that the
pharmacy did not sell 1 or 2 ml syringes, the research
staff would ask the pharmacist whether other kinds of
syringes were for sale, and then decline to purchase any
alternative syringes that were available. All purchases of
1 or 2 ml syringes either as single syringes or in packs of
ten were counted as a successful purchase.
A debriefing form was completed after each pharmacy
syringe purchase test that included information about
the type, number and price of syringes purchased, and, if
the purchase was unsuccessful, research staff provided
additional comments. Statistical analysis was performed
with SAS software (version 9.1, Cary, NC). Fisher’s Exact
Test was used to explore associations of pharmacy types
with measures of syringe access.
Results
Citywide pharmacy mapping
A total of 965 pharmacies were identified citywide (see
Additional file 1). All were retail pharmacies and could
be divided into three types: chain pharmacies (n = 694),
independent pharmacies (n = 189) that included veterin-
ary, homeopathic and clinic-based pharmacies, and
pharmacies subsidized through a governmental program
(n = 82) to provide certain citizens with low-priced med-
ical supplies. No significant statistical associations were
found between HIV prevalence and pharmacy density on
the district level regardless of whether pharmacy density
was measured per square kilometer or per 100,000
inhabitants (p = 0.61 and p = 0.24, respectively) (see
Additional file 2).
Pharmacy telephone survey
The telephone survey was conducted with the 108 phar-
macies identified in the two selected city districts: 89
(82%) reported having 1 or 2 ml syringes available for
sale, and 19 (18%) reported stocking neither type. How-
ever, 19 pharmacies that reported stocking 1 or 2 ml
syringes over the phone survey later declined to sell
them in the purchasing test, claiming not to stock them.
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The syringe purchase test script was developed on the
results of the qualitative interviews with a convenience
sample of 26 IDUs (18 males and 8 females) who
reported injecting within 30 days prior to the interview.
Three of the eight females were sex workers. Twenty-
four respondents reported heroin as their drug of choice,
one respondent reported methadone, and one respondent
reported homemade ephedrine-based stimulants.
Twenty respondents believed that pharmacists could
distinguish IDUs from other customers either by their
appearance (n = 14) or based on the purchase of a glass
bottle of Naphazoline and 1 or 2 ml syringe (n = 6),
which was reported as a standard purchase made by
IDU as was mentioned by 13 interviewees.
“Pharmacists don’t sell insulin syringes and
Naphazoline because they know that junkies use
Naphazoline as a cooker for heroin.” (Heroin user,
female, 26 years old)
Difficulties in purchasing 1 or 2 ml syringes were
reported by 23 interviewees. Four noted that pharma-
cists openly asked them to leave the pharmacy and in
two of those instances threatened to call the police. One
participant described being asked to leave the pharmacy
repeatedly by one specific pharmacist every time he tried
to purchase syringes.
“Pharmacists who are normal persons just tell you
that they don’t have syringes. In other words, they talk
to you in this way if they don’t want to be rude.
However, most of the time they just. . .told me to get
away twice saying – “If you start to argue we will call
the police.” (Heroin user, male, 30 years old)
“Some [pharmacists] are just telling you without
shame: “We have nothing – no insulin syringes, no
Naphazoline – go away from here!” (Heroin user,
male, 35 years old)
“Another pharmacist does sell, but this one [in the
same pharmacy] doesn’t have syringes any time we
come. She is always saying something like – “I have
nothing. . . get away from here. . . you are junkies.”
(Heroin user, male, 34 years old)
Four respondents reported witnessing pharmacists
selling syringes to other customers who respondents
believed were non-IDU customers while their ownrequests to purchase syringes were denied by the
pharmacists.
“They look at you like you are a public enemy and
declare that they don’t have any syringes in stock.
Right afterwards some old lady comes over the
counter and purchases syringes easily.” (Heroin user,
female, 37 years old).
Six interviewees were denied purchase of a single
syringe and were offered a 10- or 50-syringe pack
instead. Four IDUs believed that pharmacists employed
this practice to discourage IDUs from going to their
pharmacy in order not to have IDUs scare off other
customers.
“Maybe they are trying to deter drug addicts [from
coming to a pharmacy]. . .in other words they have a
somewhat negative attitude to the people who use
drugs who are considered as “garbage” of society.”
(Heroin user, male, 33 years old)
“Junkies would scare off “normal public” who would
try to avoid making purchases in this pharmacy.”
(Heroin user, female, 37 years old).
Pharmacy syringe purchase test
Among 127 mapped pharmacies in two city districts,
108 were included in the syringe purchase test; 19 phar-
macies were not operating at the time of the study.
Overall, 70 (65%) of purchase attempts resulted in suc-
cessful purchase of 1 or 2 ml syringes: 49 pharmacies
sold as singles and 21 in packs of ten. When syringes
were sold, the price ranged from 2 to 10 rubles (USD
$0.07-$0.30) for a single syringe and 42 to 59 rubles
(USD $1.40-$2.00) for packs of ten.
Petrogradskiy district
Five of the 29 mapped retail pharmacies were not
located. The final list of 24 pharmacies included one
pharmacy involved in the governmental subsidy pro-
gram, one independent pharmacy, and 22 chain pharma-
cies. Research staff were able to purchase syringes in 11
(46%) pharmacies: nine (38%) pharmacies sold single
syringes and two (8%) pharmacies sold packs of ten
(Table 1).
We could not purchase syringes in 13 (54%) pharma-
cies (one pharmacy involved in the governmental sub-
sidy program and 12 chain pharmacies); of these, five
refused to sell to our research staff although it had been
reported during the phone survey the day before that
they had such syringes in stock.
Table 1 Syringe sales at pharmacies in two districts,
St. Petersburg, Russia
Petrogradskiy Viborgskiy P value*
Number of Pharmacies 24 84
Refused to sell (total) 13 (54%) 25 (30%) 0.03
Stocked but refused to sell 5 (21%) 14 (17%) 0.76
Don’t stock at all 4 (17%) 7 (8%) 0.25
Don’t stock right now 4 (17%) 4 (5%) 0.07
Sold 1 or 2 ml syringes (total) 11 (46%) 59 (70%) 0.03
As singles 9 (38%) 40 (48%) 0.48
As 10 packs only 2 (8%) 19 (23%) 0.15
Pharmacy type selling syringes
Subsidized through
governmental program
0 of 1 7 of 8 0.22
Chain 10 of 22 44 of 63 0.07
Independent 1 of 1 8 of 13 1.00
* P value obtained from Fisher’s Exact Test.
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Fourteen of the 98 mapped retail pharmacies, were not
located. The final list of 84 pharmacies included eight
pharmacies involved in the governmental subsidy pro-
gram, 13 independent pharmacies, and 63 chain phar-
macies. Research staff were able to buy syringes in 59
pharmacies (70%): 40 (48%) as single syringes and 19
(22%) as packs of ten (Table 1).
At 25 (30%) pharmacies (19 chain, one involved in the
governmental subsidy program, and five independent) re-
search staff could not purchase syringes; of these, 14
reported stocking 1 or 2 ml syringes during the telephone
survey the day before but refused to sell to our staff.
Overall, purchasers were almost three times more
likely to successfully buy syringes in the Viborgskiy
district compared to the Petrogradskiy district (OR, 2.79;
95% CI, 1.10 – 7.06, p = 0.032).
Discussion
The data presented in this manuscript constitute the
first part of a project designed to assess the feasibility of
conducting HIV prevention or treatment interventions
through pharmacies in St. Petersburg. This phase of the
study focused on determining access to syringes, a major
component in HIV prevention for IDUs, by providing
simple descriptive evidence of the density of pharmacies
in the city of St. Petersburg and documenting the extent
to which pharmacies in two districts provide syringe
access to IDUs. First, we found no evidence to support
the hypothesis that pharmacy density may have played a
role in the HIV epidemic among IDUs, finding no asso-
ciation of density with HIV prevalence. This suggests
that the presence of pharmacies alone may not guaran-
tee sufficient access to syringes for IDUs to accomplish areduction in injection risks or prevent HIV transmission.
We then explored if this was due to pharmacists’ unwill-
ingness to sell syringes to IDUs and found that, in two
districts, approximately two-thirds of the pharmacies
sold the types of syringes preferred by IDUs either as
singles or in packs of ten. Even though the ability to pur-
chase a pack of ten was considered as successful, it still
could be considered a barrier to immediate syringe
access since its price is considerably higher than for a
single syringe. Furthermore, carrying a pack of syringes
may be more noticeable and consequently increase risk
of police harassment. Although the proportion differed
by district, the data suggest that pharmacies can play in
important role in HIV prevention efforts by expanding
IDUs’ access to sterile syringes. Nevertheless, the quali-
tative data revealed that many barriers to expanded
syringe access remain. Additional research is required to
understand and account for the threefold difference in
successful purchases between the two study districts.
Our findings parallel a previous study conducted in
2003 in three Russian cities – Moscow, Volgograd, and
Barnaul – in which pharmacies were determined to be
the predominant source of syringe supply for IDUs, pro-
viding approximately one syringe per day to the IDUs
interviewed in these cities [15]. However, the prevailing
attitudes and perceptions of pharmacists and IDUs that
may influence syringe access remain unclear in different
cities across the Russian Federation, and additional
research is needed to clarify this issue.
Our results demonstrate that even in locations in
which no laws or regulations restrict access to syringes
for IDUs, access may still be limited, in part, by pharma-
cists’ decisions not to stock the types of syringes favored
by IDUs or to refuse to sell syringes to customers
perceived to be IDUs. These practices are similar to
those observed in pharmacies in other countries [35,36].
Interventions aimed at improving pharmacists’ attitudes
about serving IDU customers warrant development and
evaluation.
In this context, pharmacies may be a promising venue
for HIV prevention because of the existing laws/regula-
tions and the density of pharmacies in major cities.
Evaluating whether pharmacy networks may be used to
expand existing or implement new and comprehensive
prevention services for IDUs is important in developing
interventions. In this phase of the study we did not
collect data from pharmacists who are and are not will-
ing to sell syringes to IDUs to determine: (1) if the reluc-
tance of the latter group can be overcome and (2) what
incentives might encourage pharmacists to expand
syringe access to and provide other services for IDUs.
These efforts are currently under way in the next phase
of our project that includes discussions with pharmacists
and public health and safety officials.
Fedorova et al. BMC Public Health 2013, 13:183 Page 6 of 7
http://www.biomedcentral.com/1471-2458/13/183Several limitations to this study must be noted. First, it
is limited to St. Petersburg, and the findings may not be
generalized to other locations. Second, the lack of correl-
ation between pharmacy density and HIV prevalence
could have been influenced by other social and behav-
ioral factors (e.g., syringe sharing, police activities) which
were not assessed as part of this study. Third, according
to the preliminary data analysis of the qualitative inter-
views, the primary factor IDUs mentioned as a reason
for unsuccessful syringe purchases was the pharmacists’
negative attitude towards IDUs. Further analysis is
needed to assess other factors such as gender and the
number of years injecting drugs that may elicit differen-
tial discrimination. The data analysis presented in this
manuscript was focused on the developing the syringe
purchase test script. Fourth, attempts to purchase syrin-
ges as part of this study were not made by actual IDUs,
and the success rate noted herein may represent an
overestimate. It is possible that IDUs who attempt to
purchase syringes may encounter greater difficulty in
purchasing syringes based on their behaviors or physical
appearance. Finally, all of the purchases were made by
male Russian research staff between the ages of 31 and
40 years old. Individual characteristics that may influ-
ence the purchase transaction such as gender, ethnicity
or age were not tested.Conclusions
The description of the current situation regarding access
to HIV prevention materials through pharmacies is the
first phase in a multi-phase process aiming to develop and
implement effective interventions to improve the health of
IDUs. This study is the first effort in Russia to apply a sci-
entific approach of combining epidemiological, behavioral,
qualitative, social, and geographical data to the process of
developing IDU-focused HIV prevention programs. The
results of the present study reveal that, despite the absence
of legal limitations on availability of syringes, about one-
third of pharmacies refused to sell syringes. Among the
potential interventions that may improve access to syrin-
ges and reduce HIV among IDUs in St. Petersburg would
be a policy change to include syringes in the federal list of
mandatory medicinal products that would require phar-
macies to stock syringes and interventions aimed at im-
proving pharmacists’ attitudes about selling syringes and
reducing the stigmatization of IDUs.Additional files
Additional file 1: Distribution of pharmacies by type and HIV
prevalence by districts. Displays distribution of pharmacies by type and
shows HIV prevalence by district level (St. Petersburg, Russia; 2009). Three
pharmacy types are presented: government-supported, chain andindependent. Data on HIV prevalence (measured per 100,000 inhabitants)
is divided in 10 categories.
Additional file 2: Data on HIV prevalence and pharmacies’ density
by district. Displays data on HIV prevalence and pharmacies’ density in
each of 18 city’s districts. Pharmacies’ density is measured per square
kilometer and per 100,000 inhabitants.
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